NCT00807859 2022-11-08Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerAmgenPhase 1 Completed65 enrolled
NCT00511459 2015-10-29Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer PatientsAmgenPhase 2 Completed228 enrolled